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Metallothioneins (MT) represent low molecular weight proteins that are sup-
posed to fulfil several functions. They participate in the cell cycle, protect cells
from oxidative stress, control levels of heavy metals and participate in multidrug
resistance processes, particularly in cases of alkylating drugs. The present study
aimed at evaluation of proliferation intensity (Ki67, PCNA) in ovarian cancers
treated using cisplatin and paclitaxel, as related to expression of MT.
The experiments were performed on samples originating from 10 patients oper-
ated on due to ovarian cancer. The material originated from the first operations
or second-look operations. All the patients were treated with cisplatin and pacli-
taxel. Immunocytochemical reactions using antibodies to MT, Ki67 and PCNA
were performed in paraffin sections originating from the cases studied. Statisti-
cal analysis was performed using Statistica software. The studies demonstrated
no relation between expression of MT on the one hand and intensity of prolifer-
ation before or after chemotherapy on the other hand (gamma correlation,
p > 0.05). The results indicate that expression of MT is not related to resistance
to treatment using cisplatin and paclitaxel.
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INTRODUCTION
Ovarian cancer occupies 3rd place in the list of
morbidity due to malignant tumours of the genital
system in women in Western and Northern Europe
and in USA and 5th place among all malignant tu-
mours in women. Worldwide, the tumour exhibits
persisting growth in incidence. In Poland in 1992
the incidence was 11.1 per 100,000 women [5]. The
location of ovarian cancers leads to the tumours
being recognised only at an advanced stage of their
development. Therefore, in a significant fraction of
cases of the disease surgery has to be accompanied
by chemotherapy. At present the most popular drug
set used in the treatment of ovarian cancer includes
paclitaxel and cis- or carboplatin [4].
Numerous studies have suggested a relation be-
tween increased expression of metallothioneins (MT)
and resistance of tumour cells to cytostatic drugs and,
in particular, alkylating drugs (cis- and carboplatin)
[2]. Metallothioneins are low molecular weight pro-
teins (6–7 kDa) of a chain of 61 or 62 amino acids.
They are characterised by a high content of cystein
residues and a low content of aromatic amino acids.
Their unique property involves capacity to bind heavy
metals [3]. Hagrman et al. [1] noted that MT may also
bind cisplatin molecules. This mechanism might ex-
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plain the potential linkage between expression of MT
and the resistance of tumours to alkylating drugs.
The present study aimed at evaluating the intensity
of proliferation markers (Ki67, PCNA) in samples of ova-
rian cancers originating from first operations or from
second-look operations following treatment with cispl-
atin and paclitaxel, as related to the expression of MT.
MATERIAL AND METHODS
The studies were performed on samples of ova-
rian cancers originating from 10 patients subject-
ed to surgery in 2000–2001, in the Department of
Gynaecology and Obstetrics, University of Medical
Sciences, Poznań (Table 1). In all the cases H+E-
-stained preparations were made, which were ex-
amined by two pathologists. In paraffin sections
originating from the studied cases and obtained
during the first operations and upon second-look
operations, immunocytochemical reactions were
performed using mouse monoclonal antibodies
against MT (clone E9), Ki67 (clone MIB-1) and PCNA
(clone PC10). In every case a negative control was
run, using the Mouse Primary Negative Control. The
antigens under investigation were visualised em-
ploying LSAB2 and DAB kits. In the cases of Ki67
and PCNA the sections being studied were boiled
in Antigen Retrieval Solution. All the reagents orig-
inated from Dako Cytomation, Denmark. MT expres-
sion was quantitated using the semiquantitative IRS
scale (Table 2) [6], while in the cases of Ki67 and
PCNA the percentage of positive cells was taken into
account. The results obtained were subjected to sta-
tistical analysis using the Statistica 98 PL software.
RESULTS AND DISCUSSION
The immunocytochemical reactions performed
enabled the following pattern of reactions to be
documented:
— in the case of MT colour reaction was obtained
in the cell nuclei and in the cytoplasm, of vari-
able intensity in individual cases (Fig. 1, Table 3);
— in the cases of Ki67 and PCNA colour reaction was
obtained localised in the cell nuclei, of variable
intensity in individual cases (Fig. 2, 3, Table 3).
Table 1. Studied cases — diagnoses
First operation Second-look operation
Carcinoma solidum Adenocarcinoma serosum
adenoides partim solidum
Adenocarcinoma Cystadenocarcinoma
endometroides endometrioidale
Adenocarcinoma Adenocarcinoma
serosum papillare serosum
Adenocarcinoma Adenocarcinoma
serosum serosum
Adenocarcinoma serosum Foci carcinomatosi
Carcinoma solidum Carcinoma solidum
adenoides serosum adenoides clarocellulare
Adenocarcinoma serosum Adenocarcinoma
endometroides
Adenocarcinoma serosum Adenocarcinoma
clarocellulare
Adenocarcinoma serosum Adenocarcinoma serosum
Adenocarcinoma serosum Adenocarcinoma serosum
Table 2. Quantitation of immunocytochemical reaction intensity using ImmunoReactiv Score scale according to Remmele
Percentage of positive cells Score Reaction intensity Score
No positive cells 0 No reaction 0
< 10% positive cells 1 Weak colour reaction 1
10–50% positive cells 2 Moderate intensity of colour reaction 2
51–80% positive cells 3 Intense colour reaction 3
> 80% positive cells 4
Table 3. Mean intensity of immunocytochemical reactions in the studied groups
Tested antigen First operation Second-look operation
MT 5.9±3.98 5.2±3.36
Ki67 42.3±29.94 11.1±10.64
PCNA 61±30.26 54±28.75
495
Paweł Surowiak et al., The expression of metallothionein (MT)
Statistical calculations failed to document a rela-
tionship between MT expression and intensity of
proliferation in individual groups and between the
groups (gamma correlation; p > 0.05). Using the
Mann-Whitney U test, it was demonstrated that only
in the case of Ki67 did intensity of expression differ
between the groups, as it was significantly lower in
material obtained in second-look operations (follow-
ing chemotherapy; p = 0.02).
The references quoted in the Introduction described
a relationship between expression of MT in tumour
cells and resistance to alkylating drugs [1, 2]. In our
study proliferative antigens (Ki67 and PCNA) served as
an index of sensitivity to chemotherapy. No relation-
ship could be found between expression of MT and
that of Ki67 and PCNA. The lack of any relationship
suggests that a weak relation or no relation links MT
expression and resistance to cisplatin. It is probable
that proteins from the group of ABC transporters play
a more significant role in this phenomenon.
In our study we have shown that expression of
Ki67 has been significantly lower following chemo-
therapy. No such differences could have been ob-
served in PCNA. Most probably Ki67 represents
a more reliable index of proliferation.
REFERENCES
1. Hagrman D, Goodisman J, Dabrowiak JC, Souid AK
(2003) Kinetic study on the reaction of cisplatin with
metallothionein. Drug Metab Dispos, 31: 916–923.
2. Hengstler JG, Pilch H, Schmidt M, Dahlenburg H,
Sagemuller J, Schiffer I, Oesch F, Knapstein PG, Kaina B,
Tanner B (2001) Metallothionein expression in ovarian
cancer in relation to histopathological parameters and
molecular markers of prognosis. Int J Cancer, 95:
121–127.
3. Kagi JHR (1991) Overview of metallothionein. Meth-
ods Enzymol, 205: 613–626.
4. Markman M (2003) Optimizing primary chemothera-
py in ovarian cancer. Hematol Oncol Clin North Am,
17: 957–968.
5. Markowska J (ed.) Rak jajnika. Springer PWN, Warszawa
1997.
6. Remmele W, Stenger HE (1987) Recommendation for
uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-
-ICA) in breast cancer tissue. Pathologe, 8: 138–140.
Figure 1. Immunocytochemical localisation of metallothionein in
cells of ovarian cancer (× 400).
Figure 3. Immunocytochemical localisation of PCNA in cells of
ovarian cancer (× 200).
Figure 2. Immunocytochemical localisation of Ki67 in cells of
ovarian cancer (× 200).
